Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure...
Neoadjuvant Chemoimmunotherapy in Patients With Early-Stage NSCLC
In a systematic review and meta-analysis reported in JAMA Network Open, Banna et al found that neoadjuvant chemoimmunotherapy was associate...
FDA Approves Trastuzumab Biosimilar Trastuzumab-strf
The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of...
FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, the U.S. Food and Drug Administration (FDA) granted traditional approval to tisotumab vedotin-tftv (Tivdak) for patients with recurrent...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends...
Susan Faye Dent: Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?
Kelly Hewitt and Laura J. Esserman: Reframing DCIS as an Opportunity for Cancer Prevention
Garth Strohbehn, Allen Lichter, and Mark Ratain: Sotorasib, the Poster Child for Project Optimus
Kevin B. Knopf and Charles L. Bennett: Generic Drug Shortages and Essential Cancer Medicines
Stuart M. Lichtman: All Adult Oncologists Are Geriatric Oncologists
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Targeting Rare, Actionable Alterations in Advanced Non–Small Cell Lung Cancer
Pembrolizumab With Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer
On January 12, 2024, pembrolizumab (Keytruda) was approved for use with chemoradiotherapy for treatment of patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
DUO-E Trial: Durvalumab-Based Treatment With or Without Olaparib Boosts Progression-Free Survival in Endometrial Cancer
In the phase III DUO-E trial, a first-line treatment regimen that includes chemotherapy plus the checkpoint inhibitor durvalumab followed by maintenance durvalumab, with or without the PARP inhibitor olaparib, significantly improved progression-free survival in patients with advanced or recurrent...
Finding Early Female Role Models Helped Shape a Notable Career in Oncology
Elizabeth M. Jaffee, MD, Deputy Director of The Sidney Kimmel Comprehensive Cancer Center, Baltimore, was born in Brooklyn, New York, in a place and time she found exhilarating during her early years. “We didn’t have a lot of money—actually, we were poor. But I had a lot of freedom walking around...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Breakthrough Prize, ‘Oscars of Science,’ Celebrates 2024 Laureates in Life Sciences
On September 14, 2023, the Breakthrough Prize Foundation announced the winners of the 2024 awards, honoring an esteemed group of the world’s researchers for their impactful scientific discoveries, including a subset responsible for substantial progress in the understanding and treatment of major...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
